FUP-COVID: Follow-up of Critical COVID-19 Patients

Sponsor
Uppsala University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04474249
Collaborator
Uppsala University Hospital (Other)
300
1
29.2
10.3

Study Details

Study Description

Brief Summary

The study will follow COVID-19 patients who required intensive care after 3-6 months and one year after discharge from the ICU with functional level as well as organ function to assess recovery after COVID-19. Blood and urine will be collected for biobanking.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The study will follow COVID-19 patients who required intensive care at Uppsala University Hospital and were included in the Uppsala COVID-19 biobank. The patients will be contacted after three to six months for a first follow-up with assessment of functional level in activities of daily life, psychiatric symptoms, neurological symptoms and working capacity as well as specific organ functions. The organ functions will include circulation, respiration, coagulation, immune function and kidney function. In addition, blood and urine will be collected for biobanking.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    300 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Uppföljning av Patienter Som intensivvårdats för COVID-19
    Actual Study Start Date :
    Jun 25, 2020
    Anticipated Primary Completion Date :
    Dec 1, 2022
    Anticipated Study Completion Date :
    Dec 1, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    COVID-19

    Patients with PCR-confirmed COVID-19 who were treated in the intensive care unit.

    Outcome Measures

    Primary Outcome Measures

    1. Mortality [Within 90 days after admission to ICU.]

      Death

    2. Mortality [Within 1 year after admission to ICU.]

      Death

    3. Renal recovery [At follow-up three to six months after ICU discharge.]

      Return of renal function measured as CKD stage.

    4. Renal recovery [At follow-up one year after ICU discharge.]

      Return of renal function measured as CKD stage.

    5. Respiratory recovery [Three to six months from discharge from ICU]

      Respiratory function as assessed by a clinician

    6. Working capacity [Three to six months from discharge from ICU]

      6 min walk test

    7. Quality of life score [Three to six months from discharge from ICU]

      Quality of Life assessed using the 36-item short form survey by RAND.

    8. Cognitive recovery [Three to six months from discharge from ICU]

      Cognitive screening using the Montreal Cognitive Assessment.

    9. Frailty [Three to six months from discharge from ICU]

      Screening for frailty using the Clinical Frailty Scale-9.

    10. Activities of Daily Life [Three to six months from discharge from ICU]

      Screening of functional level for Activities of Daily Life using the 5-level EQ-5D.

    11. Anxiety [Three to six months from discharge from ICU]

      Screening for anxiety using the Generalised Anxiety Disorder 7-item scale.

    12. Depression [Three to six months from discharge from ICU]

      Screening for depression using the Patient Health Questionnaire 9.

    13. Neurological recovery [Three to six months from discharge from ICU]

      Neurological function as assessed by a clinician

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • PCR-verified Covid-19

    • Treated in ICU

    Exclusion Criteria:
    • Pregnant of breastfeeding

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Uppsala University Hospital Uppsala Sweden 75185

    Sponsors and Collaborators

    • Uppsala University
    • Uppsala University Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Uppsala University
    ClinicalTrials.gov Identifier:
    NCT04474249
    Other Study ID Numbers:
    • EPM-2020-02697
    First Posted:
    Jul 16, 2020
    Last Update Posted:
    Oct 26, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Uppsala University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 26, 2021